Rafael (NYSE:RFL) reported top-line results from its pivotal Phase III TransportNPC study evaluating Trappsol Cyclo for Niemann-Pick Disease Type C, a rare, progressive genetic disorder. The company said it remains on track to submit a New Drug Application to the U.S. Food and Drug Administration in
Micron's revenue surged 432% over two years while Qualcomm's declined, widening a gap that raises questions about sector dynamics and competitive positioning.
XPH delivered 19% higher returns over five years despite half the volatility. XBI's 165 holdings offer broader exposure but with a 53% maximum drawdown.
Inventiva (NASDAQ:IVA) said it expects to report top-line results in the fourth quarter of 2026 from its fully enrolled Phase III NATiV3 trial of lanifibranor in patients with metabolic dysfunction-associated steatohepatitis, or MASH.
Chief Executive Officer Andrew Obenshain said the final patient
Nokia trades at a steep premium valuation while Verizon generates nearly 13x more net income on a 12.4% margin, a stark contrast in profitability and value.
Howard Hughes (NYSE:HHH) shareholders elected all 11 board nominees, approved the company’s advisory executive-compensation proposal and ratified KPMG as independent auditor for 2026, according to preliminary results announced at the company’s annual meeting.
Executive Chair Bill Ackman said each d
Peoples Bancorp (NASDAQ:PEBO) has agreed to acquire Rockville, Maryland-based Capital Bancorp Inc. in an all-stock transaction valued at approximately $728 million, a deal management described as transformational because it would add scale, national specialty businesses and a more diversified earnin
Liberty Silver (OTCMKTS:BHLL) outlined plans to combine Bunker Hill and Silver47, a transaction the company said would create a U.S.-focused, multi-asset mining company centered on silver and other strategic metals.
During the presentation, the company said Bunker Hill has entered production at its
Sagimet Biosciences (NASDAQ:SGMT) said its licensed partner Ascletis reported positive 52-week results from an open-label extension study of denifanstat, an oral fatty acid synthase, or FASN, inhibitor being evaluated for moderate-to-severe acne vulgaris in China.
The company also outlined plans fo
Grindr (NYSE:GRND) said it has agreed to acquire PurposeMed Inc., the parent company of Freddie, a Canadian telehealth provider of HIV pre-exposure prophylaxis, or PrEP, that is expanding in the United States.
Chief Executive Officer George Arison described the transaction as the company’s first ma
ASML's momentum has flipped the script — it now outpaces Qualcomm in recent quarters after trailing for years, raising questions about whether this inversion will stick.
